Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: 7 | Mind Blowing Facts

Warning of future deaths risk after three babies who had contaminated feed died

Three premature babies received total parenteral nutrition feed, contaminated by Bacillus cereus, while undergoing care in hospital.

Evening Standard

The UK’s NHS to roll out free antismoking pill. Will it work?

The UK’s National Health Service hopes the drug will help reduce the cost of treating serious illnesses.

Al Jazeera

Alzheimer’s treatment donanemab is not a ‘miracle drug’ – not providing it on the NHS is the right choice

There was frustration in some corners of the media when it was announced that a new drug to slow the progression of Alzheimer’s was not going to be made available on the NHS.

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

Alzheimer’s drug approved in the UK, but it won’t be available on the NHS – here’s why

The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.

The Conversation

Doctors urged to look out for weight loss jab ‘misuse’

The medicines regulator has also urged medics to warn patients of side effects.

Evening Standard

Tens of thousands of UK dementia patients to be enrolled in clinical trials

News of the £20m scheme comes as new drug for Alzheimer’s was rejected for use on NHS in England

The Guardian - UK

New Alzheimer’s drug rejected for NHS use – because it’s not worth the money

Alzheimer’ patients in UK left behind over regulator’s decision to reject use of new drugs

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Alzheimer’s drug rejected for widespread use by NHS spending watchdog

Donanemab is a so-called disease-modifying treatment.

Evening Standard

Donanemab – what we know about the latest Alzheimer’s drug

The drug is one of the new ‘disease modifying’ treatments for Alzheimer’s disease.

Evening Standard

Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research

The Independent UK

What you need to know about lecanemab – the Alzheimer’s drug rejected for NHS use

The drug has been developed by Eisai, a Japanese pharmaceutical company, and is sold under the brand name Leqembi

The Independent UK

What is Lecanemab and who makes it? Alzheimer’s drug gets approval but will not be available on the NHS

NICE says drug is not cost effective and shares fears of side effects

Evening Standard

First drug to slow Alzheimer’s progression will not be made available on the NHS

The spending watchdog has recommended that a drug shown to slow the progression of Alzheimer’s disease should not be rolled out on the NHS.

The Independent UK

UK health regulator rejects lecanemab as treatment for Alzheimer’s

Decision by Nice to rule out drug being available on NHS comes despite medicines licensing body giving green light

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Weight-loss jab to be used to prevent other health problems

Some 17,600 people took part in the trial and were either prescribed Wegovy or a dummy drug

The Guardian - UK

UK needs Covid-style push on dementia drugs, says ex-head of vaccine taskforce

Kate Bingham says ageing population means tackling dementia must be treated as economic imperative

The Guardian - UK

Manchester graduate who sold Viagra-style drugs online is jailed

Antoine Kolias invented own branding and said the medicines were a ‘natural remedy’ for erectile dysfunction

The Guardian - UK

Boss of US firm given £4bn in UK Covid contracts accused of squandering millions on jets and properties

Exclusive: Rishi Sunak’s team helped fast-track deal with firm founded by Charles Huang, who says contracts generated $2bn profit

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Warning over asthma drug after 500 neuropsychiatric reactions reported in young children

UK medicines regulator says information accompanying montelukast will alert users to risk of mood and behaviour changes

The Guardian - UK

Concerns as cross-sex hormones available online for just £11 a month

Experts fear children questioning their gender may turn to hidden economy to obtain hormones illegally

The Guardian - UK

Drug that could slow womb cancer to be rolled out by NHS in England

Dostarlimab or Jemperli, an immunotherapy used alongside chemotherapy, could extend life expectancy

The Guardian - UK

Safety fears over asthma drug after young children suffer severe side effects

Campaigners call for more warnings on montelukast, after reports of night terrors, depression and other mental health events

The Guardian - UK

‘A healthy kid dies and there has been no change’: parents’ anger over lack of warnings for blockbuster asthma drug

Teenager Harry Miller took his own life two years after being prescribed montelukast. His family say they were not made aware of the reported psychiatric side-effects of the drug

International Business Times UK

New MedTech Funding To Predict Diseases And Make Treatments Available To UK Patients

The UK government has awarded medtech funding to eight UK medtech companies which are developing pathbreaking tests and AI detection tools for faster treatment of life-threatening diseases, reducing the burden of NHS.

International Business Times UK

UK Government Launches New Medicinal Study To Better Prevent Strokes

The UK government has launched a pilot project to analyse the blood samples of UK stroke patients who experience side effects to understand the roles of genetic influence in stroke prevention medicines.

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Alzheimer Research UK

152 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.